BSTC
BioSpecifics Technologies Corp.

246
Loading...
Loading...
BioSpecifics Technologies Corp., a biopharmaceutical company, is engaged in the development of an injectable collagenase for various indications primarily in the United States. It provides injectable collagenase under the XIAFLEX name for the treatment of Dupuytren’s contracture and Peyronie’s disease. The company also develops XIAFLEX injectable collagenase for frozen shoulder, cellulite, human lipoma, canine lipoma, and uterine fibroid indications, as well as for keloids, hypertrophic scars, scarred tendons, glaucoma, herniated intervertebral discs, and as an adjunct to vitrectomy indications. It has a development and license agreement with Auxilium Pharmaceuticals, Inc. The company was founded in 1957 and is headquartered in Lynbrook, New York.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
N/A

Frequently Asked Questions

What is Market Cap of Biospecifics Technologies Corp.?
What is the 52-week high for Biospecifics Technologies Corp.?
What is the 52-week low for Biospecifics Technologies Corp.?
What was Biospecifics Technologies Corp. stock price yesterday?
What is the PE ratio of Biospecifics Technologies Corp.?
What is the Price-to-Book ratio of Biospecifics Technologies Corp.?
What is the 50-day moving average of Biospecifics Technologies Corp.?

Latest BSTC News

View
No BSTC news at the moment.

Advertisement|Remove ads.

Advertisement|Remove ads.